Skip to main content

Nystagmus 3, Congenital, AD

OMIM ID:

autosomal dominant

Nystagmus 3, Congenital, AD

Alternate Names

NYS3

Defective Genes

?

Clinical Characteristics

Ocular Features

The nystagmus is horizontal in type and accentuated by fixation and decreased by convergence.  It also increases during smooth pursuit and by lateral gaze.  There may be components of jerk, circular, and pendular nystagmus.  The nystagmus may be present at birth.

Systemic Features

No systemic disease is present.   

Genetics

Inheritance

No specific mutation has been found but 3 individuals in one family shared a haplotype suggesting a locus at 7p11.2.  The pedigree pattern suggests autosomal dominant inheritance.  A four generation family with male to male transmission and a balanced 7;15 translocation has been reported with a similar phenotype.

Other forms of congenital nystagmus transmitted in a similar autosomal pattern are: NYS2, NYS4, and NYS7.

X-linked recessive transmission patterns have also been identified for congenital nystagmus: NYS1, NYS5, and NYS6.

 

Pedigree

Autosomal dominant

Autosomal dominant disorders require only one mutation for the disease to be expressed.  Since an affected parent has two chromosomes, only one of which has the mutant gene, parents can expect that half (50%) of their children will receive that one and inherit the disease.  It is common for individuals that inherit the mutation, however, to not have evidence of the disease (nonpenetrance).

Image
Sample pedigree of autosomal dominant inheritance

Autosomal dominant inheritance leads to a vertical pattern of transmission

Treatment & Management

There is no effective cure for congenital nystagmus but some patients can benefit from extraocular muscle surgery, correction of refractive errors, and low vision aids.

Selected Resources

Publications

Displaying 1 - 2 of 2

Exclusion of Chromosome Regions 6p12 and 15q11, but Not Chromosome Region 7p11, in a German Family with Autosomal Dominant Congenital Nystagmus

PubMedID: 9806847

Subcutaneous Low-Dose Interleukin-2 plus Alpha Interferon in Advanced Malignant Melanoma

PubMedID: 8236501